OBJECTIVES

: Inflammatory bowel disease (IBD) is a complex group of diseases including ulcerative colitis (UC) and Crohn’s disease (CD). In Kingdom of Saudi Arabia (KSA), the prevalence of UC and CD were 0.24% and 0.2%, respectively. The Ministry of Health (MOH) conducted a class review of all biologics used for IBD management. This study assessed the current total cost of UC and CD management using Adalimumab, infliximab and Ustekinumab (UC only) in patients who failed to respond to conventional therapy and the budgetary impact of including Vedolizumab and/or Certolizumab for the management of CD and Vedolizumab and/or Golimumab for the management of UC.

METHODS : An excel based model was developed to assess two scenarios: “Current Scenario“ where UC and CD were managed using Adalimumab, Infliximab and/or Ustekinumab and “Alternative Scenarios” where UC and CD were managed using the current drugs in addition to Vedolizumab, Golimumab and/or Certolizumab. The model considered direct health costs such as drug acquisition, drug administration, adverse events management, healthcare resources utilization across different responses, and probabilities of dose escalation. The model inputs were retrieved from literature whenever available and validated by key experts through face-to-face interviews. The market shares of new drugs were varied based on experts’ insights on drugs positioning and plausible uptake scenarios. The total market shares of the new drugs, individually or combined, ranged from 0% to 25% in UC and from 0% to 11% in CD

RESULTS

: In MOH, the current total costs of UC and CD management over 5 years were SAR 235.9 million and 430.6 million; respectively. The uptake of any of the drugs, resulted in 1% to 2.2% increase in the total budget of IBD management over 5 years.

CONCLUSIONS

: The adoption of one or more new biologics would minimally increase the total cost of IBD management